title: Current options in oral antiplatelet strategies during percutaneous coronary interventions.
abstract: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y(12) receptor blocker is the         standard of care to prevent recurrent ischemic event occurrence in patients undergoing         percutaneous intervention. Glycoprotein IIb/IIIa receptor inhibitors are used in addition         to DAPT in the highest-risk clinical settings. The persistent occurrence of ischemic         events in the presence of DAPT and the irrefutable demonstration of clopidogrel         response variability are two potent arguments against the widely practiced nonselective         or "one-size-fits-all" strategy of administering clopidogrel therapy and provides a strong         rationale for monitoring clopidogrel therapy. New, potent P2Y(12) inhibitors such as         prasugrel and ticagrelor are associated with greater platelet inhibition, faster onset         of action, and better overall clinical outcomes compared with clopidogrel, but are         associated with more non-surgery-related bleeding than clopidogrel. The inhibition         of the platelet thrombin receptor may provide additional benefits in attenuating         ischemic event occurrence in selected high-risk patients treated with DAPT.
authors.affiliation: Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD, USA.
authors.forename: Udaya S
authors.initials: US
authors.lastname: Tantry
authors.forename: Paul A
authors.initials: PA
authors.lastname: Gurbel
mesh_terms: D000284:Administration, Oral; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors